Parkinson’s Disease Pipeline Review H1 2018 Drug Development and Pipeline


    The research report Parkinson’s Disease Pipeline Review H1 2018 provides comprehensive information on the therapeutics under development for Parkinson’s Disease Pipeline Review H1 2018, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. “Parkinson’s Disease Pipeline Review H1 2018 pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Complete research report on H1 2019 pipeline review of Parkinson’s Disease Pipeline Review H1 2018 with market data tables and figures, spread across 881 pages is available at

    Companies Involved in Therapeutics Development are AbbVie Inc
    AC Immune SA
    Acorda Therapeutics Inc
    Addex Therapeutics Ltd
    Aeolus Pharmaceuticals Inc
    Affichem SA
    AFFiRiS AG
    AlfaSigma SpA
    Allergan Plc
    Amabiotics SAS
    Amarantus Bioscience Holdings Inc
    American Gene Technologies International Inc
    Amneal Pharmaceuticals Inc
    Anavex Life Sciences Corp
    Antoxis Ltd
    Aoxing Pharmaceutical Company Inc
    APeT Holding BV
    ApoPharma Inc
    Araclon Biotech SL
    ArmaGen Inc
    Arrien Pharmaceuticals LLC
    AstraZeneca Plc
    Auritec Pharmaceuticals Inc
    AVM Biotechnology LLC
    Axovant Sciences Ltd
    Bactevo Ltd
    Berg LLC
    Bial – Portela & Ca SA
    Bio-Modeling Systems SAS
    BioArctic AB
    BioElectron Technology Corp
    Biogen Inc
    BioHealthonomics Inc
    Biopharm GmbH
    Blackthorn Therapeutics Inc
    BlueRock Therapeutics
    BrainStorm Cell Therapeutics Inc
    C4X Discovery Holdings PLC
    Calico LLC
    Cantabio Pharmaceuticals Inc
    Cardax Inc
    Carmot Therapeutics Inc
    Carna Biosciences Inc
    Cavion LLC
    Cellix Bio Pvt Ltd
    CHA Bio & Diostech Co Ltd
    Chipscreen Biosciences Ltd
    Clera Inc
    Clevexel Pharma SAS
    Copernicus Therapeutics Inc
    Corium International Inc
    Crossject SA
    Curemark LLC
    Daewoong Pharmaceutical Co Ltd
    Denali Therapeutics Inc
    Diffusion Pharmaceuticals Inc
    Dizlin Medical Design AB
    Domain Therapeutics SA
    Easywell Biomedical Inc
    Eli Lilly and Co
    Energenesis Biomedical Co Ltd
    Evgen Pharma Plc
    Fabre-Kramer Pharmaceuticals Inc
    Forma Therapeutics Inc
    FPRT Bio Inc
    Fulcrum Therapeutics Inc
    Genecode AS
    Generon (Shanghai) Corp Ltd
    Genervon Biopharmaceuticals LLC
    GenKyoTex SA
    Genmab A/S
    Genosco Inc
    Genzyme Corp
    H. Lundbeck AS
    Hanmi Pharmaceuticals Co Ltd
    Hemostemix Inc
    Heptares Therapeutics Ltd
    Herantis Pharma Plc
    Hisamitsu Pharmaceutical Co Inc
    HitGen LTD
    ICB International Inc
    Icure Pharmaceutical Inc
    ID Pharma Co Ltd
    Immungenetics AG
    Impel NeuroPharma Inc
    India Globalization Capital Inc
    InnoMedica Holding AG
    Intec Pharma Ltd
    International Stem Cell Corp
    Intra-Cellular Therapies Inc
    Io Therapeutics Inc
    Ionis Pharmaceuticals Inc
    IRLAB Therapeutics AB
    Jeil Pharmaceutical Co Ltd
    Kainos Medicine Inc
    Khondrion BV
    Kissei Pharmaceutical Co Ltd
    Kyowa Hakko Kirin Co Ltd
    Lead Discovery Center GmbH
    Living Cell Technologies Ltd
    Longevity Biotech Inc
    Luye Pharma Group Ltd
    M et P Pharma AG
    M’s Science Corp
    M3 Biotechnology Inc
    MedGenesis Therapeutix Inc
    MedImmune LLC
    Merck & Co Inc
    Merz Pharma GmbH & Co KgaA
    Metabolic Solutions Development Company LLC
    MimeTech Srl
    Minerva Neurosciences Inc
    Mission Therapeutics Ltd
    Mitochon Pharmaceuticals Inc
    Montisera Ltd
    Motac Neuroscience Ltd
    Neonc Technologies Inc
    Netherlands Translational Research Center BV
    Neuren Pharmaceuticals Ltd
    NeuroDerm Ltd
    Neurodyn Life Sciences Inc
    NeuroGeneration Inc
    NeuroNascent Inc
    NeurOp Inc
    Neuropore Therapies Inc
    New World Laboratories Inc
    Newron Pharmaceuticals SpA
    nLife Therapeutics SL
    Novartis AG
    Novo Nordisk AS
    Omeros Corp
    Oncodesign SA
    OPKO Health Inc
    OptiNose US Inc
    Orion Corporation
    Oryzon Genomics SA
    Oxford BioMedica Plc
    ParkCell AB
    Parkure Ltd
    Peptron Inc
    Pfizer Inc
    Pharma Two B Ltd
    Pharmicell Co Ltd
    Pharnext SA
    Phenomenome Discoveries Inc
    Phoenix Biotechnology Inc
    Plex Pharmaceuticals Inc
    Prana Biotechnology Ltd
    Priavoid GmbH
    ProMIS Neurosciences Inc
    Promius Pharma LLC
    Prosetta Biosciences Inc
    Prothena Corp Plc
    QR Pharma Inc
    reMYND NV
    Rich Pharmaceuticals Inc
    Sage Therapeutics Inc
    SanBio Inc
    Saniona AB
    Serina Therapeutics Inc
    Shire Plc
    SignPath Pharma Inc
    SK Biopharmaceuticals Co Ltd
    STATegics Inc
    Stealth BioTherapeutics Inc
    Sumitomo Dainippon Pharma Co Ltd
    Sun Pharma Advanced Research Company Ltd
    Sunovion Pharmaceuticals Inc
    Synthonics Inc
    Takara Bio Inc
    TechnoPhage SA
    Teikoku Pharma USA Inc
    Teva Pharmaceutical Industries Ltd
    Titan Pharmaceuticals Inc
    UCB SA
    UniQure NV
    Varinel Inc
    Voyager Therapeutics Inc
    vTv Therapeutics Inc
    Xoc Pharmaceuticals Inc

    The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinson’s Disease Pipeline Review H1 2018.Parkinson’s Disease Pipeline Review H1 2018. The pipeline guide reviews pipeline therapeutics for Parkinson’s Disease Pipeline Review H1 2018. The pipeline guide reviews pipeline therapeutics for Parkinson’s Disease Pipeline Review H1 2018by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Parkinson’s Disease Pipeline Review H1 2018 therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Parkinson’s Disease Pipeline Review H1 2018therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Parkinson’s Disease Pipeline Review H1 2018.

    If you want sample copy of the report feel free to reach us at

    This research report will help you to:-

    • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

    • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

    • Find and recognize significant and varied types of therapeutics under development.

    • Classify potential new clients or partners in the target demographic.

    • Develop tactical initiatives by understanding the focus areas of leading companies.

    • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

    • Formulate corrective measures for pipeline projects by understanding pipeline depth and focus of Indication therapeutics.

    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

    • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

    Avail Discount on this report @

    About Us: – MarketInsightsReports provides syndicated Market research reports to industries, organizations or even individuals with an aim of helping them in their decision making process. MarketInsightsReports has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
    +1 (704) 266-3234 | mail to: Sales